-
May 2, 2012
MS Boon: Many Drugs On The Way, But Will Payors Swallow The Cost?
Two new oral drugs for relapsing remitting multiple sclerosis are poised for a near-term launch, and more drugs that work through different mechanisms of action could soon follow.
Read More
-
April 18, 2012
How Many Times Per Month Do Certain Types of Patients Seek Online Health Information?
U.S. adults with multiple sclerosis go online to look up health information about seven times per month, according to a survey by Manhattan Research.
Read More
-
April 18, 2012
ALK Mutation Testing for NSCLC on the Rise among Oncologists, BioTrends Survey Finds
A recent survey tracking the adoption of ALK mutation testing among oncologists suggests that doctors are becoming increasingly comfortable personalizing treatment strategies for non-small cell lung cancer patients based on clinical factors and genomic data.
Read More
-
April 18, 2012
Spotlight On: EMA accepts submission for first biosimilar antibody product
The European Medicines Agency has published its list of new product applications, among which is a submission for biosimilar Remicade (infliximab), the branded version of which is marketed in Europe by Merck & Co.
Read More
-
April 12, 2012
Janssen Looks To Differentiate Anticoagulant Xarelto With Broad Label
Johnson & Johnson subsidiary Janssen Inc. believes that its oral anticoagulant Xarelto (rivaroxaban) is on its way to having the broadest label of any of the novel anticoagulant agents.
Read More
-
April 10, 2012
BlackBerry-maker RIM courts physicians with Bold
The last time BlackBerry-maker Research In Motion (RIM) could convincingly claim to be the favorite device of doctors was probably May 2010.
Read More
-
March 28, 2012
Janssen Plans New U.S. Filing For Xarelto, Based On Positive EINSTEIN-PE Results
With the results from the EINSTEIN-PE non-inferiority trial, which showed a 50% reduction in major bleeding compared to the standard of care, Janssen Inc. is planning a second-quarter filing with FDA for its anti-coagulant Xarelto (rivaroxaban) in treatment and secondary prevention of symptomatic pulmonary embolism.
Read More
-
March 18, 2012
Princeton venture capital firm and Russians collaborate on life sciences
Domain Associates is teaming up with the Russian government-backed investment group Rusnano in an ambitious deal to bring new medicines and medical devices to Russia’s emerging healthcare market.
Read More
-
March 6, 2012
Pain-Wracked Migraine Patients’ Unmet Needs Targeted by Map’s Inhaled Drug
Companies led by Map Pharmaceuticals Inc. (MAPP) are pushing to develop better treatments for the 36 million Americans who get migraines. Regulators are set to announce this month if Map’s Levadex, an inhaled form of DHE that can be taken at home, can be marketed. If so, it may be worth $1 billion a year by 2020.
Read More
-
March 1, 2012
Early Signs For Takeda’s TAK-875 Suggest The GPR40 Agonist Could Take On Other Oral Antidiabetics
Full publication of Phase II results for Takeda Pharmaceutical Co. Ltd.’s diabetes drug TAK-875 – the most advanced GPR40 agonist – in the Lancet Feb. 27 suggests a profile potentially competitive with other new oral classes, such as DPP-4 and SGLT-2 inhibitors.
Read More
-
March 1, 2012
MM&M Awards 2012: How to Win an Award
The deadline for entries to the MM&M Awards (April 13) is fast approaching. To help give you an edge, we asked our 2011 judges to offer a few choice tips, based on their experiences of the review process.
Read More
-
February 26, 2012
Bluetooth low energy enabled iPhone applications for mobile health
Cambridge Consultants will demonstrate its latest Bluetooth low energy (BLE) iPhone 4S applications using CSR's BLE devices at this year's Mobile World Congress.
Read More
-
February 23, 2012
Heart groups see 'seamless' merger
When Memphis Heart Clinic and Stern Cardiovascular Foundation complete their merger on March 1, all but one of the Heart Clinic's locations will remain and all of its employees will work for Stern, a company official said.
Read More
-
February 21, 2012
Health care reform has hospitals jockeying to protect market share, grow more efficient
Expect to see increased consolidations among area hospitals, more doctors leave private practice to become employees and health care reform pick up steam despite the controversy surrounding the federal health care reform law.
Read More
-
February 10, 2012
Alkermes readies for diabetic treatment push
CEO Richard Pops says Alkermes’ new Type 2 diabetes treatment has the potential to be an attractive choice for physicians and patients.
Read More